Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Choosing a prediabetes treatment often begins with a familiar question: How can clinicians help prevent elevated glucose from progressing to type 2 diabetes? A major network meta-analysis offers one of the broadest answers yet. Researchers evaluated 378 randomized controlled trials involving 113,122 participants and compared lifestyle strategies, metformin, incretin-based therapies, and numerous other interventions. The findings suggest some newer treatments may produce striking reductions in diabetes risk. However, the results also reinforce an important clinical lesson: the intervention with the strongest trial estimate is not automatically the right choice for every patient.
Table of Contents
- What 378 randomized trials revealed
- Lifestyle intervention remains clinically important
- Metformin and incretin-based therapies
- Turning population evidence into individual treatment
- Conclusion
- Frequently Asked Questions
What 378 Trials Reveal About Treating Prediabetes
Published in Clinical and Translational Medicine, the analysis included randomized trials of adults with prediabetes and compared pharmacologic and nonpharmacologic strategies. Researchers examined progression to type 2 diabetes along with changes in HbA1c, fasting plasma glucose, and two-hour glucose.
The strongest estimated reduction in progression to type 2 diabetes occurred with dual GLP-1/GIP receptor agonist therapy. Compared with control, this strategy produced a relative risk of 0.10, with a 95% confidence interval of 0.05 to 0.21. GLP-1 receptor agonists followed with a relative risk of 0.26, while metformin combined with intensive lifestyle intervention produced a relative risk of 0.27.
Those numbers are compelling. However, they should not be interpreted as a simple prescribing hierarchy. Network meta-analysis combines direct and indirect comparisons across many studies. Therefore, differences in trial populations, treatment duration, adherence, baseline weight, and other factors matter when applying the results.
Moreover, preventing diabetes is only one outcome. Safety, tolerability, cost, weight goals, comorbidities, patient preferences, and long-term feasibility can all influence the right approach for a particular patient.
Lifestyle Intervention Still Has an Essential Role
The results do not make lifestyle intervention obsolete. Instead, they add to decades of evidence showing that nutrition, physical activity, weight management, and behavioral support can meaningfully alter diabetes risk.
The landmark Diabetes Prevention Program found that intensive lifestyle intervention reduced diabetes incidence by 58% compared with placebo during the original trial, while metformin reduced incidence by 31%. Long-term follow-up showed that both approaches continued to delay diabetes, although differences between groups narrowed over time. Diabetes in Control has previously reviewed these long-term diabetes prevention findings.
Importantly, lifestyle treatment does more than change a glucose measurement. Physical activity can improve insulin sensitivity, while weight loss can address an important driver of metabolic risk. Dietary changes may also improve blood pressure, lipids, and overall cardiometabolic health.
Structured programs may make these changes easier to sustain. As Diabetes in Control has discussed in its coverage of structured lifestyle programs for prediabetes, ongoing coaching and behavioral support can turn general advice into a practical intervention.
Metformin, GLP-1 Drugs, and Dual Incretin Therapy
Metformin remains one of the most established pharmacologic options considered for diabetes prevention. Its long clinical history, relatively low cost, and extensive safety data make it different from newer therapies. Previous research also suggests that its preventive benefit is not identical across all patient groups.
The new meta-analysis, however, puts incretin-based therapies in the spotlight. GLP-1 receptor agonists showed a large reduction in diabetes progression, while dual GLP-1/GIP receptor agonists produced an even larger estimated effect. In addition, dual incretin therapy, GLP-1 receptor agonists, physical activity, and curcumin were among the interventions associated with HbA1c reductions exceeding 0.3 percentage points at one year.
Still, these findings require context. Drugs such as semaglutide and tirzepatide may be prescribed for approved indications such as obesity or type 2 diabetes, depending on the specific product and patient. Their benefits for weight reduction can also affect diabetes risk. Yet a favorable result in a prevention meta-analysis does not mean every person with prediabetes should receive an incretin drug.
Likewise, medications should not automatically replace nutrition, physical activity, and weight-management support. Instead, the evidence supports a broader conversation about matching treatment intensity to individual risk.
Turning Trial Results Into Individualized Care
Perhaps the most useful message from 113,122 participants is that clinicians now have more evidence-supported options for managing prediabetes than they did in the past. The challenge is deciding who needs which intervention.
A patient with mildly elevated HbA1c and few additional risk factors may have very different needs from someone with obesity, rising glucose, previous gestational diabetes, or several cardiometabolic risk factors. Consequently, absolute benefit can vary even when the relative treatment effect appears impressive.
Clinicians should also consider whether an intervention can be maintained. A treatment that performs well during a controlled trial may deliver less benefit when cost, adverse effects, access, adherence, or treatment discontinuation become issues.
Therefore, the new analysis should strengthen shared decision-making rather than replace it. Clinicians can use the findings to discuss the relative evidence for lifestyle intervention, metformin, weight-management strategies, and incretin-based therapy while considering each patient's broader health profile.
For patients seeking individualized guidance, consultation with a qualified healthcare professional can help translate population-level evidence into an appropriate care plan.
Conclusion
The 378-trial network meta-analysis provides a remarkably broad view of the evidence on preventing progression from prediabetes to type 2 diabetes. Dual GLP-1/GIP receptor agonists showed the largest estimated reduction in progression to type 2 diabetes, followed by GLP-1 receptor agonists and metformin combined with intensive lifestyle intervention.
However, the findings do not create a universal treatment ladder. Lifestyle intervention remains important, metformin retains a substantial evidence base, and newer incretin therapies introduce powerful options for selected patients. Ultimately, effective diabetes prevention depends on combining high-quality evidence with individual risk, treatment goals, access, safety, and patient preferences.
Frequently Asked Questions
Which interventions were most effective in the new prediabetes analysis?
Dual GLP-1/GIP receptor agonist therapy produced the largest estimated reduction in progression to type 2 diabetes compared with control. However, that finding should be interpreted within the limitations of network meta-analysis and individualized clinical care.
Does lifestyle change still work for prediabetes?
Yes. Strong evidence supports structured lifestyle intervention involving physical activity, nutrition changes, and weight management. Earlier major trials demonstrated substantial and durable reductions in diabetes risk.
Should everyone with prediabetes take metformin?
No. Metformin may be appropriate for selected higher-risk patients, but treatment decisions should account for individual risk factors, expected benefit, tolerability, and patient preferences.
Can GLP-1 drugs prevent type 2 diabetes?
Randomized trial evidence included in the new analysis indicates that GLP-1 receptor agonists can substantially reduce progression to type 2 diabetes among studied participants with prediabetes. However, medication selection should be based on the patient's clinical situation and approved indications.
Can prediabetes return to normal glucose levels?
Yes. Some people with prediabetes can return to normal glucose regulation, particularly after meaningful lifestyle and weight changes. Nevertheless, continued monitoring remains important because future diabetes risk may persist.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.